SEC Comment Letter 0000000000-24-004084 to Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936) (CYTOF)
Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936)
Date: April 16, 2024 · CIK: 0001601936 · Accession: 0000000000-24-004084
AI Filing Summary & Sentiment
File numbers found in text: 333-278594
Letter
United States securities and exchange commission logo April 16, 2024 Thomas Meyer, PhD Chief Executive Officer Altamira Therapeutics Ltd. 254 Chapman Rd, Ste 208 Newark, DE 19702 Re:Altamira Therapeutics Ltd. Registration Statement on Form F-1 Filed April 10, 2024 File No. 333-278594 Dear Thomas Meyer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Alex Dinur, Esq.
Show Raw Text
United States securities and exchange commission logo
April 16, 2024
Thomas Meyer, PhD
Chief Executive Officer
Altamira Therapeutics Ltd.
254 Chapman Rd, Ste 208
Newark, DE 19702
Re:Altamira Therapeutics Ltd.
Registration Statement on Form F-1
Filed April 10, 2024
File No. 333-278594
Dear Thomas Meyer:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Alex Dinur, Esq.